Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis.
Makoto NaganumaKenji WatanabeSatoshi MotoyaHaruhiko OgataToshiyuki MatsuiYasuo SuzukiLyann UrsosShigeru SakamotoMitsuhiro ShikamuraTetsuharu HoriJovelle FernandezMamoru WatanabeToshifumi HibiTakanori KanaiPublished in: Journal of gastroenterology and hepatology (2021)
This study suggested the possibility that concomitant immunomodulator use may be beneficial to maintain the clinical efficacy of vedolizumab.